淋巴瘤患者1例预防使用聚乙二醇化重组人粒细胞刺激因子的病例分析
|
摘要
目的探讨临床药师在监护抗肿瘤药物相关不良反应中的作用,为淋巴瘤化疗所致粒细胞减少症患者的药学治疗提供参考。方法临床药师通过1例淋巴瘤患者预防使用聚乙二醇化重组人粒细胞刺激因子的病例,结合患者病史和相关指南分析认为患者目前的情况符合化疗所致粒细胞减少症的二级预防,提出治疗意见,并对患者实施全面的药学监护。结果临床药师的参与,提高了整个治疗过程的依从性和安全性,减轻了化疗所致粒细胞减少症给患者带来的痛苦。结论临床药师通过在肿瘤科进行全面的药学监护,从药学的角度,对临床治疗起到积极的作用。
Objective To explore the role of clinical pharmacists in monitoring adverse reactions related to anti-tumor drugs,and to provide reference for the pharmaceutical treatment of patients with granulocytopenia caused by lymphoma chemotherapy. Methods Clinical pharmacists concluded that the current situation of the patient was consistent with the secondary prevention of chemotherapy-induced granulocytopenia through the analysis of a case of lymphoma patient who was with preventive use of plyethylene glycol recombinant human granulocyte colony-stimulating factor.Clinical pharmacists put forward treatment suggestions and implement comprehensive pharmaceutical monitoring for patients. Results The participation of clinical pharmacists improved the compliance and safety of the whole treatment process and alleviated the pain caused by chemotherapy-induced granulocytopenia. Conclusion Clinical pharmacists play a positive role in clinical treatment from the perspective of pharmacy through comprehensive pharmacological monitoring in the department of oncology.
Objective To explore the role of clinical pharmacists in monitoring adverse reactions related to anti-tumor drugs,and to provide reference for the pharmaceutical treatment of patients with granulocytopenia caused by lymphoma chemotherapy. Methods Clinical pharmacists concluded that the current situation of the patient was consistent with the secondary prevention of chemotherapy-induced granulocytopenia through the analysis of a case of lymphoma patient who was with preventive use of plyethylene glycol recombinant human granulocyte colony-stimulating factor.Clinical pharmacists put forward treatment suggestions and implement comprehensive pharmaceutical monitoring for patients. Results The participation of clinical pharmacists improved the compliance and safety of the whole treatment process and alleviated the pain caused by chemotherapy-induced granulocytopenia. Conclusion Clinical pharmacists play a positive role in clinical treatment from the perspective of pharmacy through comprehensive pharmacological monitoring in the department of oncology.
引文
[1]张利娟,王凤玮.弥漫大B细胞淋巴瘤的治疗进展[J].中华临床医师杂志,2014,8(11):2127-2131.
[2]张智慧.弥漫大B细胞淋巴瘤的治疗进展[J].肿瘤预防与治疗,2012,25(5):316-321.
[3]何小慧,周生余,董梅,等.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少的有效性分析[J].中国肿瘤临床,2015,14(12):626-631.
[4]吴凤鹏,张明,王军.PEG-rhG-CSF对同期放化疗所致Ⅲ度粒细胞缺乏患者挽救性治疗的临床研究[J].河北医药,2014,10(22):925-926.
[5]徐淑英,董力枫,蒋晓燕,等.聚乙二醇化重组人粒细胞集落刺激因子防治乳腺癌术后化疗所致中性粒细胞减少的疗效和护理[J].中华危重症医学杂志,2018,11(3):210-212.
[6]Bodey GP,Buckley M,Sathe YS,et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia[J].Ann Intern Med,1966,64(2):328-340.
[7]姚达娜.聚乙二醇化重组人粒细胞集落刺激因子在淋巴瘤化疗后的应用[J].承德医学院学报,2018,35(3):208-209.
[8]杨晟,何小慧,刘鹏,等.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少的有效性分析[J].新药临床试验,2015,42(12):626-631.
[9]Kuderer NM,Dale DC,Crawford J,et al.Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy:a systematic review[J].J Clin Oncol,2007,25(21):3158-3167.
[10]中国肿瘤学会指南工作委员会.肿瘤放化疗相关中性粒细胞减少症规范化管理指南[J].中国肿瘤杂志,2017,39(11):868-878.
[11]周世勇,王华庆,张会来,等.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少症临床疗效观察[J].中国肿瘤临床,2011,38(18):1154-1158.
[12]姚达娜,吴福群.淋巴瘤化疗后粒细胞减少预防中聚乙二醇化重组人粒细胞集落刺激因子的应用观察[J].中国医学创新,2018,15(13):31-34.
[13]俞铭洁,吴雯婷,倪婷婷.聚乙二醇化重组人粒细胞集落刺激因子用于卵巢癌及宫颈癌化疗的价值[J].浙江医学,2017,39(4):307-314.
[14]Liu Z,Doan QV,Malin J,et al.The conomic value of primary prophylaxis using pegfilgrastim commpared with filgrastimm in patients with breast cancer in the UK[J].Appl Health Policy,2009,7(3):193-205.
[15]Yang BB,Kido A.Pharmmacodynamics of pegfilgrastim[J].Clin Pharmacokinet,2011,50(5):295-306.
[2]张智慧.弥漫大B细胞淋巴瘤的治疗进展[J].肿瘤预防与治疗,2012,25(5):316-321.
[3]何小慧,周生余,董梅,等.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少的有效性分析[J].中国肿瘤临床,2015,14(12):626-631.
[4]吴凤鹏,张明,王军.PEG-rhG-CSF对同期放化疗所致Ⅲ度粒细胞缺乏患者挽救性治疗的临床研究[J].河北医药,2014,10(22):925-926.
[5]徐淑英,董力枫,蒋晓燕,等.聚乙二醇化重组人粒细胞集落刺激因子防治乳腺癌术后化疗所致中性粒细胞减少的疗效和护理[J].中华危重症医学杂志,2018,11(3):210-212.
[6]Bodey GP,Buckley M,Sathe YS,et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia[J].Ann Intern Med,1966,64(2):328-340.
[7]姚达娜.聚乙二醇化重组人粒细胞集落刺激因子在淋巴瘤化疗后的应用[J].承德医学院学报,2018,35(3):208-209.
[8]杨晟,何小慧,刘鹏,等.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少的有效性分析[J].新药临床试验,2015,42(12):626-631.
[9]Kuderer NM,Dale DC,Crawford J,et al.Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy:a systematic review[J].J Clin Oncol,2007,25(21):3158-3167.
[10]中国肿瘤学会指南工作委员会.肿瘤放化疗相关中性粒细胞减少症规范化管理指南[J].中国肿瘤杂志,2017,39(11):868-878.
[11]周世勇,王华庆,张会来,等.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少症临床疗效观察[J].中国肿瘤临床,2011,38(18):1154-1158.
[12]姚达娜,吴福群.淋巴瘤化疗后粒细胞减少预防中聚乙二醇化重组人粒细胞集落刺激因子的应用观察[J].中国医学创新,2018,15(13):31-34.
[13]俞铭洁,吴雯婷,倪婷婷.聚乙二醇化重组人粒细胞集落刺激因子用于卵巢癌及宫颈癌化疗的价值[J].浙江医学,2017,39(4):307-314.
[14]Liu Z,Doan QV,Malin J,et al.The conomic value of primary prophylaxis using pegfilgrastim commpared with filgrastimm in patients with breast cancer in the UK[J].Appl Health Policy,2009,7(3):193-205.
[15]Yang BB,Kido A.Pharmmacodynamics of pegfilgrastim[J].Clin Pharmacokinet,2011,50(5):295-306.